Latest News

Cipla receives USFDA approval for generic Isuprel injection

Cipla has received green signal for Isoproterenol Hydrochloride injection, from the US health regulator. It is used for treating cardiac problems, in the American market.

The company stated that, it has received final approval from the United States Food and Drug Administration (USFDA) for its product which is a generic version of Hospira Inc’s Isuprel injection. Further, the product is suggested for serious episodes of heart block and cardiac arrest, until electric shock or pacemaker therapy is available.

Read EquityPandit’s Technical Analysis of Cipla

Click here to check market prediction for next trading session.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.



📰
News
📈
Prediction
📊
FII / DII
👔
Advisory
Get 1-2 Index Option Trades Daily